Neurotoxicity Clinical Trial
Official title:
A Randomized, Controlled, Multicenter Phase II Clinical Trial of Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by Albumin-bound Paclitaxel Chemotherapy in Lung Cancer Patients
The purpose of this study is to determine whether monosialoganglioside are effective in the prevention of neurotoxicity induced by albumin-bound paclitaxel chemotherapy in lung cancer patients, and improve the quality of life of patients.
Lung cancer patients received a single-agent albumin-bound paclitaxel chemotherapy are included in this trial. Patients are randomly assigned into the experimental group and blank control group based on segmented block randomized method. After enrollment, patients will complete at least chemotherapy and GM1 injection/blank control. During the 3w per cycle chemotherapy, albumin-bound paclitaxel is conducted in D1 and D8, GM1(40mg+250ml N.S) is injected from D1 to D8. Neurotoxicity evaluation and quality of life assessment will be conducted every cycle and 3m/6m after the chemotherapy. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05510596 -
Magnetic Resonance Imaging in Immune Effector Cell-Associated Neurotoxicity Syndrome
|
N/A | |
| Completed |
NCT01399372 -
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
|
Phase 2 | |
| Completed |
NCT01196442 -
Electrical Stimulation Pain Therapy in Treating Chronic Pain and Numbness Caused By Chemotherapy in Patients With Cancer
|
N/A | |
| Completed |
NCT00775645 -
S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy
|
Phase 3 | |
| Recruiting |
NCT00884767 -
Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin
|
Phase 2 | |
| Recruiting |
NCT03330964 -
Clinical Trial of Electroacupuncture Stimulation on Prevention and Treatment of Oxaliplatin Neurotoxicity
|
N/A | |
| Active, not recruiting |
NCT04150913 -
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
|
Phase 2 | |
| Completed |
NCT01417507 -
Natural History of Brain Function, Quality of Life, and Seizure Control in Patients With Brain Tumor Who Have Undergone Surgery
|
N/A | |
| Completed |
NCT00471445 -
Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients
|
Phase 3 | |
| Completed |
NCT00365768 -
Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors
|
Phase 2 | |
| Withdrawn |
NCT00734773 -
Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL
|
Phase 0 | |
| Completed |
NCT00305799 -
Hearing Loss and Dizziness in Patients Receiving Oxaliplatin for Solid Tumors
|
N/A | |
| Completed |
NCT00018967 -
Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate
|
N/A | |
| Active, not recruiting |
NCT00978458 -
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
|
Phase 3 | |
| Completed |
NCT05094154 -
Effect of Antibiotic Choice On ReNal Outcomes (ACORN)
|
Phase 4 | |
| Completed |
NCT02486198 -
Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer
|
Phase 3 | |
| Not yet recruiting |
NCT05798884 -
Electro-acupuncture for the Prevention and Treatment of Oxaliplatin-induced Neurotoxicity in Colorectal Cancer Patients
|
N/A | |
| Completed |
NCT02864030 -
PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment
|
Phase 4 | |
| Completed |
NCT00755313 -
Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer
|
N/A | |
| Completed |
NCT00369564 -
Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer
|
Phase 3 |